feed,title,long_url,short_url
Investors,"Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market",https://www.investors.com/news/technology/insmed-stock-non-cystic-fibrosis-bronchiectasis-brensocatib/,https://da.gd/KZYL6
